XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms XigduoPMS
- Sponsors AstraZeneca
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2019 Planned End Date changed from 30 Jun 2019 to 31 Aug 2019.